New hope for Hard-to-Treat breast cancer? early trial launches
NCT ID NCT07235176
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called QLS1304 combined with standard hormone therapy in people with advanced ER+/HER2- breast cancer whose disease has worsened after at least one prior hormone treatment. The trial has two phases: first finding the best dose, then checking how well it works. About 300 participants will take part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QLS1304 tablet combined with endocrine therapy (fulvestrant, AI, or CDK4/6i)
- What this could lead to
- If successful, this could provide a new treatment option for advanced ER+/HER2- breast cancer patients who have stopped responding to standard endocrine therapy.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with only 300 participants, so safety and effectiveness are not yet proven. The combination may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ER+/HER2- BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Cancer Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••